Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: ABH
Latest Price: 0.26p  (0,00%)
52-week High: 0.67p
52-week Low: 0.20p
Market Cap: 8.51M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Angel Biotechnology
www.angelbio.com
Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.
Pdf

Angel Biotechnology to provide consultancy services for Fusion IP’s latest spin-out Progenteq

8th Feb 2010, 3:23 pm Angel Biotechnology to provide consultancy services for Fusion IP’s latest spin-out Progenteq

Bio-pharmaceutical contractorAngel Biotechnology (AIM: ABH) has signed a contract with university IP commercialisation company Fusion IP’s (AIM: FIP) latest spin-out company, Progenteq. The company will provide the newly established venture with consultancy and development services as Progenteq develops and commercialises its novel cartilage replacement therapy. The terms of the contract have not been disclosed.  
    
"We are delighted to be working with Progenteq on its novel cell therapy.  Being awarded this contract further acknowledges our experience and expertise in the field of regenerative medicine development and manufacturing”, Angel's chief operating officer Gordon Sherriff said.

Progenteq is developing a novel cartilage replacement, using technology developed by Professor Charlie Archer's research group at Cardiff University's School of Biosciences. Archer’s group successfully isolated a defined population of cells, with stem-cell-like properties, from the articular cartilage which surround the main bones in the knee joint. According to Progenteq these cells, when derived from donors, can be used to grow a large tissue-bank that is suitable for insertion into patients when needed. This procedure is referred to as "allogeneic" cartilage replacement therapy.

Progenteq believes that this new therapy-model promises a more cost-effective cell therapy than current "autologous" approaches, where a patient’s own cells are removed, expanded and then implanted.  "We are tremendously excited by the prospect of this novel cell therapy. Angel is well placed to assist the company in its product development activities and we look forward to working with them as we progress Progenteq towards the clinic", Progenteq Director Dominic Griffiths commented.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.